Predicting population coverage of T-cell epitope-based diagnostics and vaccines

被引:586
作者
Bui, Huynh-Hoa
Sidney, John
Dinh, Kenny
Southwood, Scott
Newman, Mark J.
Sette, Alessandro
机构
[1] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, San Diego, CA 92109 USA
[2] IDM Inc, San Diego, CA 92121 USA
关键词
D O I
10.1186/1471-2105-7-153
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: T cells recognize a complex between a specific major histocompatibility complex (MHC) molecule and a particular pathogen- derived epitope. A given epitope will elicit a response only in individuals that express an MHC molecule capable of binding that particular epitope. MHC molecules are extremely polymorphic and over a thousand different human MHC (HLA) alleles are known. A disproportionate amount of MHC polymorphism occurs in positions constituting the peptide-binding region, and as a result, MHC molecules exhibit a widely varying binding specificity. In the design of peptide-based vaccines and diagnostics, the issue of population coverage in relation to MHC polymorphism is further complicated by the fact that different HLA types are expressed at dramatically different frequencies in different ethnicities. Thus, without careful consideration, a vaccine or diagnostic with ethnically biased population coverage could result. Results: To address this issue, an algorithm was developed to calculate, on the basis of HLA genotypic frequencies, the fraction of individuals expected to respond to a given epitope set, diagnostic or vaccine. The population coverage estimates are based on MHC binding and/or T cell restriction data, although the tool can be utilized in a more general fashion. The algorithm was implemented as a web-application available at http://epitope.liai.org:8080/tools/population. Conclusion: We have developed a web-based tool to predict population coverage of T-cell epitope-based diagnostics and vaccines based on MHC binding and/or T cell restriction data. Accordingly, epitope-based vaccines or diagnostics can be designed to maximize population coverage, while minimizing complexity (that is, the number of different epitopes included in the diagnostic or vaccine), and also minimizing the variability of coverage obtained or projected in different ethnic groups.
引用
收藏
页数:5
相关论文
共 15 条
[1]  
Dawson DV, 2001, GENET EPIDEMIOL, V20, P87, DOI 10.1002/1098-2272(200101)20:1<87::AID-GEPI8>3.0.CO
[2]  
2-R
[3]   HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles [J].
Doolan, DL ;
Southwood, S ;
Chesnut, R ;
Appella, E ;
Gomez, E ;
Richards, A ;
Higashimoto, YI ;
Maewal, A ;
Sidney, J ;
Gramzinski, RA ;
Mason, C ;
Koech, D ;
Hoffman, SL ;
Sette, A .
JOURNAL OF IMMUNOLOGY, 2000, 165 (02) :1123-1137
[4]   HLA allele selection for designing peptide vaccines [J].
Gulukota, K ;
DeLisi, C .
GENETIC ANALYSIS-BIOMOLECULAR ENGINEERING, 1996, 13 (03) :81-86
[5]  
Imanishi T., 1992, HLA 1991, P1065
[6]   Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes [J].
Longmate, J ;
York, J ;
La Rosa, C ;
Krishnan, R ;
Zhang, M ;
Senitzer, D ;
Diamond, DJ .
IMMUNOGENETICS, 2001, 52 (3-4) :165-173
[7]   HLA gene and haplotype frequencies in the North American population - The National Marrow Donor Program Donor Registry [J].
Mori, M ;
Beatty, PG ;
Graves, M ;
Boucher, KM ;
Milford, EL .
TRANSPLANTATION, 1997, 64 (07) :1017-1027
[8]   Minimal phenotype panels - A method for achieving maximum population coverage with a minimum of HLA antigens [J].
Schipper, RF ;
vanEls, CACM ;
DAmaro, J ;
Oudshoorn, M .
HUMAN IMMUNOLOGY, 1996, 51 (02) :95-98
[9]  
Sette A, 2000, IDrugs, V3, P643
[10]  
Terasaki PI., 1998, HLA 1998, P365